Welcome to our dedicated page for Cidara Theraptcs news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Theraptcs stock.
Cidara Therapeutics, Inc. (CDTX) generates news primarily as a clinical-stage biotechnology company developing drug-Fc conjugate (DFC) therapeutics through its proprietary Cloudbreak platform. Most recent coverage focuses on CD388, a long-acting antiviral DFC designed as a non-vaccine preventative for seasonal and pandemic influenza, as well as on corporate transactions and government collaborations.
News about Cidara frequently highlights clinical trial milestones for CD388. This includes updates on the Phase 2b NAVIGATE trial in healthy unvaccinated adults and the Phase 3 ANCHOR trial in adults and adolescents at higher risk of influenza complications, including individuals with immune-compromised conditions, certain comorbidities, and adults over 65 years of age. Articles often describe trial design, enrollment progress, interim analysis plans, and safety and efficacy results reported by the company.
Investors following CDTX news will also see disclosures on regulatory interactions and designations, such as Fast Track and Breakthrough Therapy designations granted by the U.S. Food and Drug Administration (FDA) for CD388, and company commentary on plans to seek biologics license application (BLA) approval based on a single Phase 3 study. Additional coverage includes Cidara’s BARDA agreement to support expanded manufacturing and clinical development of CD388, detailing federal funding for onshoring manufacturing and additional clinical and non-clinical work.
Another major theme in Cidara’s news flow is its acquisition by Merck. Releases describe Merck’s definitive agreement to acquire Cidara through a cash tender offer and subsequent merger, the tender offer terms, and Merck’s statements about integrating CD388 into its respiratory portfolio. Updates from Merck note the successful completion of the tender offer, the planned merger to make Cidara a wholly owned subsidiary, and the expected delisting of Cidara’s common stock from the Nasdaq Global Market.
On this CDTX news page, readers can review historical and transaction-related announcements, clinical data presentations at scientific conferences, investor conference participation, and quarterly corporate updates. For those researching Cidara’s development of CD388, its Cloudbreak platform, and the transition of Cidara into Merck’s portfolio, this news feed provides a centralized view of key public communications over time.
Cidara Therapeutics (Nasdaq: CDTX) reported Q1 2021 financial results with revenue at $2.4 million, a slight decrease from $2.5 million in Q1 2020. The net loss widened to $18.3 million from $14.5 million year-over-year. Cidara secured a worldwide licensing agreement with Janssen for its Cloudbreak influenza AVCs, bringing an upfront payment of $27 million and potential total funding of $753 million. R&D expenses increased to $15.8 million, influenced by ongoing rezafungin trials and antiviral platform costs. Cidara remains focused on advancing its product pipeline and anticipates key developments by year-end.
Cidara Therapeutics (Nasdaq: CDTX) is set to present at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 1:30 PM ET. CEO Jeffrey Stein will provide a corporate overview highlighting the company’s commitment to developing long-acting therapeutics for severe fungal and viral infections. Cidara's lead candidate is rezafungin, part of its innovative Cloudbreak® antiviral platform. Investors can access the live audio webcast on the company’s website.
Cidara Therapeutics (CDTX) has entered a collaboration with Janssen Pharmaceuticals, securing exclusive worldwide rights to develop and commercialize its antiviral conjugate, CD388, aimed at combating influenza. The agreement includes an upfront payment of $27 million, with potential milestone payments and R&D funding amounting to $753 million. Cidara will advance CD388 through Phase 2 clinical trials, funded by Janssen, which has expertise in viral disease therapies. The collaboration aims to provide universal protection against seasonal and pandemic influenza strains.
Cidara Therapeutics (Nasdaq: CDTX) announced on April 1, 2021, that its Compensation Committee granted stock options and restricted stock units totaling 27,000 shares to four new employees. These equity awards are part of the 2020 Inducement Incentive Plan and have a grant date exercise price of $2.66 per share, equal to the stock's closing price on the grant date. Vesting will occur over four years, subject to continuous service. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) to induce talent by offering meaningful equity compensation.
Cidara Therapeutics, Inc. (Nasdaq: CDTX) announced the upcoming presentation by CEO Jeffrey Stein, Ph.D., at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be accessible on-demand via the Investors section of the company’s website starting March 9, 2021. Cidara is focused on developing long-acting therapeutics to improve care for patients with serious fungal and viral infections, with its lead antifungal candidate being rezafungin and additional antiviral conjugates from the Cloudbreak® platform.
Cidara Therapeutics (CDTX) reported its financial results for Q4 and FY 2020, revealing revenues of $3.7 million and $12.1 million, down from $1.8 million and $20.9 million in 2019. The company faced a net loss of $21.6 million in Q4 and $72.1 million for the year, increasing from $14.0 million and $41.1 million in 2019. Cash reserves decreased to $42.9 million. Cidara emphasized its clinical progress with rezafungin and plans to report data from the ReSTORE trial by end of 2021. The company also announced new Board appointments to strengthen its management team.
Cidara Therapeutics (Nasdaq: CDTX) announced new analyses from the completed Phase 2 STRIVE trial for rezafungin, a once-weekly echinocandin, demonstrating safety and efficacy in treating candidemia and invasive candidiasis among high-risk immunocompromised patients. The overall response rate was 75% in patients treated with rezafungin compared to 66.7% for the standard of care. Additionally, rezafungin's efficacy remained unaffected by renal impairment. Cidara is advancing rezafungin through Phase 3 trials for candidemia and invasive fungal disease prevention.
Cidara Therapeutics (Nasdaq: CDTX) announced its participation in the 21st International Immunocompromised Host Society Symposium, occurring virtually from Feb. 17-19, 2021. The company will present significant findings on rezafungin, its novel once-weekly echinocandin currently in Phase 3 trials for treating serious fungal infections. Key presentations include an oral overview by Dr. Taylor Sandison and three poster presentations focused on rezafungin's efficacy. Additionally, Cidara will showcase preclinical data on its antiviral conjugate candidate, CD377, targeting influenza.
Cidara Therapeutics (Nasdaq: CDTX) announced the addition of Bonnie Bassler, Ph.D., and Carin Canale-Theakston to its board of directors. Dr. Bassler brings extensive molecular biology expertise and experience from various biotech boards, while Canale-Theakston boasts over 25 years in life sciences communications. Their appointments aim to bolster the company's focus on advancing its antifungal candidate, rezafungin, which is currently in Phase 3 trials, and its antiviral conjugate programs targeting influenza.
Cidara Therapeutics (Nasdaq: CDTX) has granted a stock option for 115,000 shares to a new employee under its 2020 Inducement Incentive Plan, effective December 31, 2020. The exercise price is $2.00 per share, equal to the closing price on the grant date. The option vests over four years, with 25% vesting after one year and the remainder in monthly installments. This award complies with Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee's hiring. Cidara focuses on long-acting therapeutics for serious fungal and viral infections, including its lead candidate, rezafungin.